METHODS AND SYSTEMS FOR PROSTATE HEALTH MONITORING

• US 20100168621A1
• Filed: 12/22/2009
• Published: 07/01/2010
• Est. Priority Date: 12/23/2008
• Status: Abandoned Application

• Current Assignee: Soar BioDynamics, Ltd.
• Original Assignee: Soar BioDynamics, Ltd.
• Inventors: Neville, Thomas B.
• Application Number:
  US12/645,002
• Publication Number:
  US 20100168621A1
• Time in Patent Office: Days
• US Class Current: 600/587
• CPC Class Codes: A61B 5/055 involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• CPC Class Codes: A61B 5/4381 Prostate evaluation or disorder diagnosis
• CPC Class Codes: A61B 5/7275 Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
• CPC Class Codes: A61B 8/08 Detecting organic movements or changes, e.g. tumours, cysts, swellings A61B8/02 - A61B8/06 take precedence
• CPC Class Codes: G01N 2800/342 Prostate diseases, e.g. BPH, prostatitis
• CPC Class Codes: G01N 33/6893 related to diseases not provided for elsewhere
• CPC Class Codes: G16H 20/10 relating to drugs or medications, e.g. for ensuring correct administration to patients
• CPC Class Codes: G16H 50/20 for computer-aided diagnosis, e.g. based on medical expert systems
• CPC Class Codes: G16H 70/60 relating to pathologies

Abstract

Disclosed herein are computer-implemented personalized probabilities determination systems and methods for use in integrated health systems and methods related to the medical conditions, such as conditions of the prostate, including benign and malignant disease. A system and method is disclosed herein for estimating trends in biomarkers and calculating the probability of different prostate medical conditions. Also disclosed herein are methods and systems relating to estimating prostate volume and probabilities of benign prostatic hyperplasia (BPH). Methods and systems relating to probabilities and feedback during treatment of prostatic conditions or diseases are also provided herein.

Claims

1. A method of detecting prostate enlargement comprising:

a) monitoring a prostate biomarker value at one or more times;

b) measuring a volume of the prostate of the subject when the prostate biomarker value is or exceeds a target value;

c) calibrating the prostate biomarker value with the volume measurement; and

d) detecting the presence or absence of prostate enlargement in the subject by measuring the prostate biomarker value.

2. The method of claim 1, wherein the calibrating step comprises determining the prostate biomarker value density.

3. The method of claim 1, wherein the prostate biomarker is PSA or fPSA.

4. The method of claim 1 further comprising monitoring the prostate biomarker value two or more times, thereby forming a prostate biomarker trend.

5. The method of claim 4, wherein the monitoring step comprises eliminating anomalous prostate biomarker values from the trend that are values outside of a tolerance.

6. The method of claim 1, wherein the measuring step comprises an ultrasound measurement.

7. The method of claim 1 further comprising calculating the probability of prostate enlargement from the prostate biomarker value.

8. A method of performing a course of medical action for prostate enlargement in a subject, the method comprising:

a) monitoring a prostate biomarker value from a subject at one or more times;

b) measuring a volume of the prostate of the subject when the prostate biomarker value is or exceeds a target value;

c) calibrating the prostate biomarker value with the volume measurement;

d) estimating the volume of the prostate by measuring the prostate biomarker value at a time after the measuring step;

e) performing a course of medical action when the estimated volume of the prostate is greater than a threshold value.

9. The method of claim 8, further comprising repeating steps d) and e) after determining the outcome of the course of medical action.

10. The method of claim 8, wherein steps c) and d) are performed by a computer system.

11. The method of claim 10, wherein said computer system comprises a device for network communication, a storage unit, and a processor.

12. The method of claim 10, wherein said computer system comprises a Monte Carlo engine.

13. The method of claim 8, further comprising calculating the probability of prostate enlargement from the prostate biomarker value.

14. The method of claim 8, wherein the calibrating step comprises determining the prostate biomarker value density.

15. The method of claim 8, wherein the prostate biomarker is PSA or fPSA.

16. The method of claim 8, further comprising monitoring the prostate biomarker value two or more times, thereby forming a prostate biomarker trend.

18. The method of claim 8, wherein the measuring step comprises an ultrasound measurement.

19. The method of claim 8, wherein the course of medical action is delivering medical treatment to said subject.

20. The method of claim 19, wherein the medical treatment is selected from a group consisting of the following:

a pharmaceutical, TURP, TUNA, and TUMT.

21. The method of claim 8, wherein the course of medical action comprises administration of medical tests.

22. The method of claim 8, wherein the course of medical action comprises medical imaging of said subject.

23. The method of claim 8, wherein the course of medical action comprises a consultation with a medical professional.

24. The method of claim 8, further comprising performing a digital rectal exam and calibrating the prostate biomarker value with the digital rectal exam results and the volume measurement.

17. The method of claim 17, wherein the monitoring step comprises eliminating anomalous prostate biomarker values from the trend that are values outside of a tolerance.

25. A method comprising:

a) establishing a Bayesian network comprising a plurality of prostatitis conditions of the prostate, wherein the priors of the Bayesian network are provided by historical data;

b) calculating a probability of a target prostatitis condition of a prostate using a trend of a prostate biomarker value over time;

c) providing the probability of the target medical condition of the prostate to the Bayesian network as a prior for the target medical condition;

d) performing a course of medical action in respect to the target medical condition and receiving the result of the course of medical action;

e) adjusting the priors of the Bayesian network according to the result; and

f) calculating the probability of the target prostatitis condition.

26. The method of claim 25, wherein the target prostatitis condition is inflammation or infection.

27. The method of claim 25, wherein the course of medical action is delivering an anti-inflammatory.

28. The method of claim 25, wherein the course of medical action is delivering an anti-biotic.

29. The method of claim 25, wherein the course of medical action is performing a white blood cell count.

30. The method of claim 25, wherein the course of medical action is culturing prostate secretions.

31. The method of claim 25, further comprising detecting a change in the prostate biomarker value after step d).

32. The method of claim 31, wherein the change demonstrates an effectiveness of a course of medical action.

33. The method of claim 25 further comprising calculating the probability of prostate cancer using the probability of the target prostatitis condition calculated in step f).

34. A method of providing a medical treatment of a prostate condition comprising:

a) providing a course of medical action to a subject with a prostate condition;

b) detecting a change in a prostate biomarker value of the subject before providing the medical treatment and during the medical treatment; and

c) adjusting the course of medical action based upon the change in the prostate biomarker value.

35. The method of claim 34, wherein the prostate biomarker is PSA or fPSA.

36. The method of claim 34, further comprising detecting a change in the prostate biomarker value at more than one time during treatment.

37. The method of claim 34, wherein the prostate biomarker over time forms a prostate biomarker trend and wherein the change in the prostate biomarker value is detected by a change in the prostate biomarker trend.

38. The method of claim 34, wherein the prostate condition is BPH.

39. The method of claim 38, wherein the course of medical action is delivering a pharmaceutical to the subject, and the adjusting of the course of medical action comprises adjusting at least one of the following:

treatment time or treatment dose.

40. The method of claim 38, wherein the course of medical action is delivering a pharmaceutical to the subject, and the adjusting of the course of medical action comprises changing the pharmaceutical being delivered during treatment.

41. The method of claim 34, wherein the prostate condition is prostatitis infection.

42. The method of claim 41, wherein the course of medical action is delivering an antibiotic to the subject, and the adjusting of the course of medical action comprises adjusting at least one of the following:

treatment time or treatment dose.

43. The method of claim 41, wherein the course of medical action is delivering a pharmaceutical to the subject, and the adjusting of the course of medical action comprises changing the pharmaceutical being delivered during treatment.

44. The method of claim 34, wherein the prostate condition is prostatitis inflammation.

45. The method of claim 44, wherein the course of medical action is delivering an anti-inflammatory to the subject, and the adjusting of the course of medical action comprises adjusting at least one of the following:

treatment time or treatment dose.

46. The method of claim 44, wherein the course of medical action is delivering a pharmaceutical to the subject, and the adjusting of the course of medical action comprises changing the pharmaceutical being delivered during treatment.